Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Calcium Gluconate Injection on Hemodynamic Variables in Cyanotic Congenital Heart Disease
IRCT20210316050726N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of calcium gluconate in Cyanotic heart disease (CCHD), sponsored by Iran University of Medical Sciences. Primary endpoint: Change in hemodynamic variables. Started Aug 2021; status: completed.
02
Drugs
calcium gluconate
03
Conditions
Cyanotic heart disease (CCHD)
Beyond the preview
Go deeper on IRCT20210316050726N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210316050726N1.